GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » ROA %

Tyme Technologies (Tyme Technologies) ROA % : -30.90% (As of Jun. 2022)


View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Tyme Technologies's annualized Net Income for the quarter that ended in Jun. 2022 was $-25.98 Mil. Tyme Technologies's average Total Assets over the quarter that ended in Jun. 2022 was $84.09 Mil. Therefore, Tyme Technologies's annualized ROA % for the quarter that ended in Jun. 2022 was -30.90%.

The historical rank and industry rank for Tyme Technologies's ROA % or its related term are showing as below:

TYME' s ROA % Range Over the Past 10 Years
Min: -356.25   Med: -135.91   Max: -23.83
Current: -26.18

During the past 11 years, Tyme Technologies's highest ROA % was -23.83%. The lowest was -356.25%. And the median was -135.91%.

TYME's ROA % is not ranked
in the Biotechnology industry.
Industry Median: -35.41 vs TYME: -26.18

Tyme Technologies ROA % Historical Data

The historical data trend for Tyme Technologies's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyme Technologies ROA % Chart

Tyme Technologies Annual Data
Trend Nov12 Nov13 Nov14 Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -90.90 -135.91 -93.59 -41.47 -23.83

Tyme Technologies Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.23 -22.16 -22.30 -30.12 -30.90

Competitive Comparison of Tyme Technologies's ROA %

For the Biotechnology subindustry, Tyme Technologies's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tyme Technologies's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyme Technologies's ROA % distribution charts can be found below:

* The bar in red indicates where Tyme Technologies's ROA % falls into.



Tyme Technologies ROA % Calculation

Tyme Technologies's annualized ROA % for the fiscal year that ended in Mar. 2022 is calculated as:

ROA %=Net Income (A: Mar. 2022 )/( (Total Assets (A: Mar. 2021 )+Total Assets (A: Mar. 2022 ))/ count )
=-23.626/( (110.263+88.015)/ 2 )
=-23.626/99.139
=-23.83 %

Tyme Technologies's annualized ROA % for the quarter that ended in Jun. 2022 is calculated as:

ROA %=Net Income (Q: Jun. 2022 )/( (Total Assets (Q: Mar. 2022 )+Total Assets (Q: Jun. 2022 ))/ count )
=-25.98/( (88.015+80.162)/ 2 )
=-25.98/84.0885
=-30.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2022) net income data. ROA % is displayed in the 30-year financial page.


Tyme Technologies  (NAS:TYME) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2022 )
=Net Income/Total Assets
=-25.98/84.0885
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-25.98 / 0)*(0 / 84.0885)
=Net Margin %*Asset Turnover
=N/A %*0
=-30.90 %

Note: The Net Income data used here is four times the quarterly (Jun. 2022) net income data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Tyme Technologies ROA % Related Terms

Thank you for viewing the detailed overview of Tyme Technologies's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tyme Technologies (Tyme Technologies) Business Description

Traded in Other Exchanges
N/A
Address
1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921
Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.
Executives
Michael Demurjian director, 10 percent owner, officer: Chief Operating Officer 157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman director, 10 percent owner, officer: CEO and Chief Science Officer 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl director 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido officer: Chief Financial Officer C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini officer: Corporate Controller 17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry director 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M officer: Acting Chief Medical Officer 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels director 220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman officer: EVP, Product Development 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor officer: President and CFO 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin officer: Chief Operating Officer 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

Tyme Technologies (Tyme Technologies) Headlines

From GuruFocus